Trial Profile
A retrospective study of Infliximab and Adalimumab assessing drug and antibody levels for clinical decision making in patients with inflammatory bowel disease.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Feb 2016
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Infliximab (Primary)
- Indications Inflammatory bowel diseases
- Focus Pharmacodynamics
- 26 Feb 2016 New trial record